March 11, 2020 / 1:13 PM / 23 days ago

BRIEF-FDA Approves Opdivo & Yervoy For Patients With Hepatocellular Carcinoma

March 11 (Reuters) - Bristol-Myers Squibb Co:

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) + YERVOY® (IPILIMUMAB) FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) PREVIOUSLY TREATED WITH SORAFENIB

* BRISTOL-MYERS SQUIBB CO - OPDIVO + YERVOY COMBINATION IS NOW APPROVED TO TREAT FOUR TYPES OF CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below